This study suggests that brodalumab (aka Siliq and Kyntheum) is associated with a higher likelihood of sustained PASI response, including complete clearance, at week 52 than comparators.

Quote:

---

Background:
Patients with moderate‐to‐severe psoriasis require long‐term treatment, yet few trials compare outcomes beyond a short‐term induction period. Quantitative comparisons of long‐term outcomes in patients with psoriasis are limited. To our knowledge, no network meta‐analysis (NMA) of such data has been performed.

Objective:
To compare novel systemic therapies, both biologic and non‐biologic, approved for moderate‐to‐severe psoriasis by conducting a systematic review (SR) and NMA of Psoriasis Area and Severity Index (PASI) outcomes measured at or around one year.

Methods:
An SR was conducted to identify studies reporting PASI 75, 90 and 100 responses. Feasibility of an NMA on maintenance phase endpoints was assessed and sources of heterogeneity considered. Data appropriate for analysis were modelled using a Bayesian multinomial likelihood model with probit link. Wherever possible, data corresponding to an intention‐to‐treat approach with non‐responder imputation was used.

Results:
Twenty‐four studies reporting outcomes at 40–64 weeks were identified, but heterogeneity in study design allowed synthesis of only seventeen. Four 52‐week RCTs comprised the primary analysis, which found brodalumab was significantly more efficacious than secukinumab, ustekinumab and etanercept. Secukinumab was also more efficacious than ustekinumab and both outperformed etanercept. In a secondary analysis, evidence from thirteen additional studies and four further therapies (adalimumab, apremilast, infliximab, ixekizumab) was included by comparing long‐term outcomes from active interventions to placebo outcomes extrapolated from induction. Results were consistent with the primary analysis: brodalumab was most effective, followed by ixekizumab and secukinumab, then ustekinumab, infliximab and adalimumab. Etanercept and apremilast had the lowest expected long‐term efficacy. Results were similar when studies with low prior exposure to biological therapies were excluded.

Conclusion:
Results suggest that brodalumab is associated with a higher likelihood of sustained PASI response, including complete clearance, at week 52 than comparators. Further long‐term active‐comparator RCT data is required to better assess relative efficacy across therapies.

Source: onlinelibrary.wiley.com

*Early view funding unknown

That is looking very good.

They only compared it to other biologicals, I see.
Would be nice to see more detailed information and see the results in spreadsheets and diagrams. As one question comes to mind... How much better is brodalumab.

(Sat-06-10-2018, 19:31 PM)Caroline Wrote: How much better is brodalumab.  

I don't know, going by post on Psoriasis Club I won't be trying it.

Yes I noticed they only named the biologicals and otezla although they state it was tested against  four other therapies but don’t say what they were, that might have been interesting

But I suspect it was funded by the maker

And like Fred having read Kyntheum / Siliq (brodalumab) would be unlikely to use it

(Sat-06-10-2018, 20:16 PM)jiml Wrote: But I suspect it was funded by the maker

Probably Jim. They will state funding once it gets published, but my guess would be the same as yours.

I do sometimes think about not publishing, but I try to keep as independent as possible hence mostly using one reputable source for news.

I also keep my own views out of the first post, but will post once others do if I have an opinion. And my opinion is there are enough other bio's out there without using this one. Do to it's track record it's obviously going to be cheaper than the others and, if they can find a little bit good from it they will.

But it is news and I try not to censor everything and give our readers a choice without using too many publications, we all have to make our own choices at the end of the day and the good thing about Psoriasis Club is we have real people giving their own opinions.

I think it is very valuable that you posted it, and I am happy that you did. It gives us the possibility to correlate and talk about it and create an opinion on it by ourselves.

(Sat-06-10-2018, 20:47 PM)Caroline Wrote: I think it is very valuable that you posted it, and I am happy that you did. It gives us the possibility to correlate and talk about it and create an opinion on it by ourselves.

Yep, that's my thinking.

(Sat-06-10-2018, 20:16 PM)jiml Wrote: And like Fred having read Kyntheum / Siliq (brodalumab) would be unlikely to use it

Just read the thread. Thats some pretty severe potential side effects.

Any posts from users on kyntheum? Just started 3 weeks ago. And got some pretty concerning side effects. Thanks

Hi Martin I don't remember reading of any other members on it, what sort of side effects are you having are they among the ones listed to look out for here Kyntheum / Siliq (brodalumab)

Hope what ever they are they aren't to serious